Quest Diagnostics Incorporated (NYSE:DGX) was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating in a research report issued on Tuesday.

A number of other research firms have also issued reports on DGX. Raymond James Financial, Inc. reiterated a “market perform” rating on shares of Quest Diagnostics in a research note on Monday. BidaskClub lowered shares of Quest Diagnostics from a “buy” rating to a “hold” rating in a research note on Monday, July 24th. Bank of America Corporation upgraded shares of Quest Diagnostics from a “neutral” rating to a “buy” rating and raised their target price for the company from $111.00 to $118.00 in a research note on Tuesday, July 25th. Zacks Investment Research lowered shares of Quest Diagnostics from a “buy” rating to a “hold” rating in a research note on Thursday, August 3rd. Finally, Credit Suisse Group reiterated a “neutral” rating and issued a $110.00 target price (up from $83.00) on shares of Quest Diagnostics in a research note on Thursday, July 13th. They noted that the move was a valuation call. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. Quest Diagnostics currently has a consensus rating of “Hold” and an average price target of $111.09.

Quest Diagnostics (NYSE DGX) opened at 93.09 on Tuesday. Quest Diagnostics has a one year low of $79.12 and a one year high of $112.97. The firm has a market cap of $12.70 billion, a price-to-earnings ratio of 18.76 and a beta of 0.69. The firm has a 50-day moving average of $106.58 and a 200-day moving average of $105.42.

Quest Diagnostics (NYSE:DGX) last posted its earnings results on Tuesday, July 25th. The medical research company reported $1.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.42 by $0.13. Quest Diagnostics had a net margin of 9.28% and a return on equity of 15.66%. The business had revenue of $1.94 billion for the quarter, compared to analyst estimates of $1.94 billion. During the same period last year, the business posted $1.34 EPS. Quest Diagnostics’s revenue was up 1.9% compared to the same quarter last year. Analysts anticipate that Quest Diagnostics will post $5.69 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another site, it was copied illegally and reposted in violation of United States and international trademark and copyright laws. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/09/28/valuengine-downgrades-quest-diagnostics-incorporated-dgx-to-hold.html.

In other news, CEO Stephen H. Rusckowski sold 53,933 shares of the firm’s stock in a transaction dated Monday, September 11th. The shares were sold at an average price of $108.16, for a total transaction of $5,833,393.28. Following the completion of the transaction, the chief executive officer now directly owns 220,049 shares of the company’s stock, valued at approximately $23,800,499.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jeffrey M. Leiden sold 296 shares of the firm’s stock in a transaction dated Friday, August 4th. The stock was sold at an average price of $106.66, for a total transaction of $31,571.36. Following the transaction, the director now directly owns 6,000 shares of the company’s stock, valued at $639,960. The disclosure for this sale can be found here. Insiders have sold a total of 161,996 shares of company stock valued at $17,517,207 over the last ninety days. 1.75% of the stock is owned by insiders.

Several large investors have recently added to or reduced their stakes in the company. Schnieders Capital Management LLC lifted its holdings in shares of Quest Diagnostics by 0.3% during the 2nd quarter. Schnieders Capital Management LLC now owns 2,366 shares of the medical research company’s stock worth $263,000 after acquiring an additional 6 shares during the period. Parallel Advisors LLC lifted its holdings in shares of Quest Diagnostics by 0.9% during the 2nd quarter. Parallel Advisors LLC now owns 1,291 shares of the medical research company’s stock worth $140,000 after acquiring an additional 12 shares during the period. First American Trust FSB lifted its holdings in shares of Quest Diagnostics by 0.3% during the 2nd quarter. First American Trust FSB now owns 4,395 shares of the medical research company’s stock worth $489,000 after acquiring an additional 14 shares during the period. Hills Bank & Trust Co. lifted its holdings in shares of Quest Diagnostics by 1.4% during the 2nd quarter. Hills Bank & Trust Co. now owns 2,560 shares of the medical research company’s stock worth $285,000 after acquiring an additional 35 shares during the period. Finally, Ferguson Wellman Capital Management Inc. lifted its holdings in shares of Quest Diagnostics by 0.9% during the 2nd quarter. Ferguson Wellman Capital Management Inc. now owns 4,300 shares of the medical research company’s stock worth $478,000 after acquiring an additional 40 shares during the period. 87.10% of the stock is owned by institutional investors.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).

Analyst Recommendations for Quest Diagnostics (NYSE:DGX)

Receive News & Stock Ratings for Quest Diagnostics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics Incorporated and related stocks with our FREE daily email newsletter.